 | Up a level |
Cohen, J. B., Engert, A., Ansell, S. M., Younes, A., Trneny, M., Savage, K. J., Ramchandren, R., Collins, G. P., Fanale, M. A., Armand, P., Zinzani, P. L., de Boer, J. P., Shipp, M. A., Santoro, A., Timmerman, J. M., Sacchi, M., Sy, O. and Kuruvilla, J. (2018). Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study. Br. J. Haematol., 181. S. 87 - 89. HOBOKEN: WILEY. ISSN 1365-2141
Jaeger, U., Engert, A., Fanale, M., Santoro, A., Armand, P., Ansell, S., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., De Boer, J. P., Kuruvilla, J., Savage, K. J., Trneny, M., Rodig, S., Shipp, M., Kato, K., Sumbul, A., Farsaci, B. and Younes, A. (2017). Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplantation: full results after extended follow-up of the multicohort, multicenter phase 2 CheckMate 205 trial. Oncol. Res. Treat., 40. S. 13 - 15. BASEL: KARGER. ISSN 2296-5262